TY - JOUR T1 - Early Alveolar Epithelial Cell Necrosis is a Potential Driver of ARDS with COVID-19 JF - medRxiv DO - 10.1101/2022.01.23.22269723 SP - 2022.01.23.22269723 AU - Kentaro Tojo AU - Natsuhiro Yamamoto AU - Nao Tamada AU - Takahiro Mihara AU - Miyo Abe AU - Takahisa Goto Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/24/2022.01.23.22269723.abstract N2 - Rationale Acute respiratory distress syndrome (ARDS) with COVID-19 is aggravated by hyperinflammatory responses even after passing the peak of viral load. However, the underlying mechanisms remain unclear.Objectives Here, we assess whether alveolar epithelial cell necrosis and subsequent releases of damage associated molecular patterns (DAMPs) at an early disease stage aggravate ARDS with COVID-19Methods In patients with COVID-19 with and without ARDS and healthy adults, serum levels of the following were quantified: an epithelial total cell death marker, cytokeratin18-M65; an epithelial apoptosis marker, CK18-M30; HMGB-1; and alveolar epithelial and endothelial injury markers, sRAGE, angiopoietin-2, and surfactant protein-D. Molecular mechanisms of alveolar epithelial cell death and effects of HMGB-1 neutralization on alveolar tissue injury were assessed using a mouse model of COVID-19-induced ARDS.Measurements and main results The levels of CK18-M65, CK18-M30, and alveolar tissue injury markers were elevated in early stages of ARDS. The median M30/M65 ratio, an epithelial apoptosis indicator, was 31.50% in patients with ARDS, a value significantly lower than that of non-ARDS patients or healthy subjects. Serum levels of HMGB-1, one of DAMPs released from necrotic cells, were also significantly elevated in ARDS versus non-ARDS patients. In a COVID-19-induced ARDS mouse model, alveolar epithelial cell necrosis involved two forms of programmed necrosis, necroptosis and pyroptosis. Finally, neutralization of HMGB-1 attenuated alveolar tissue injury in the mouse model.Conclusions Necrosis, including necroptosis and pyroptosis, seems to be the primary form of alveolar epithelial cell death, and subsequent release of DAMPs is a potential driver of COVID-19-induced ARDS.The impact of this research Alveolar tissue injury in acute respiratory distress syndrome (ARDS) with COVID-19 is aggravated by hyperinflammatory responses even after passing the peak of viral load. Our analysis of serum samples from COVID-19 patients and an animal model revealed that alveolar epithelial necrosis, including necroptosis and pyroptosis, occurs at the early disease stage of COVID-19-induced ARDS. Moreover, our data indicated that damage-associated molecular patterns released from necrotic alveolar epithelial cells are promising therapeutic targets to prevent the COVID-19 aggravation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partly supported by AMED under Grant Number JP20he0522001 and JSPS KAKENHI Grant Number 21K16575, and Grant for 2020-2021 Research Development Fund of Yokohama City University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yokohama City University Hospital institutional review boardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. ER -